Technical Analysis for CTNM - Contineum Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -0.66% | |
| Bollinger Band Squeeze | Range Contraction | -0.66% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.75% | |
| Spinning Top | Other | -2.75% | |
| Bollinger Band Squeeze | Range Contraction | -2.75% | |
| Stochastic Reached Overbought | Strength | -2.75% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 19 hours ago |
| 10 DMA Support | about 19 hours ago |
| Down 1% | about 19 hours ago |
| Rose Above Previous Day's High | about 22 hours ago |
| Up 2% | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Contineum Therapeutics, Inc. Description
Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that the Company believes, once modulated, can demonstrably impact the course of disease. The Company has a pipeline of internally-developed programs to address multiple NI&I disorders, including PIPE-791, an LPA1 receptor antagonist, in Phase 1 clinical trials for idiopathic pulmonary fibrosis and progressive multiple sclerosis, and PIPE-307, a selective inhibitor of the M1 receptor in a Phase 2 clinical trial for relapse-remitting multiple sclerosis. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Neuroscience Inflammation Multiple Sclerosis Idiopathic Pulmonary Fibrosis Small Molecule Therapies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.92 |
| 52 Week Low | 13.27 |
| Average Volume | 74,402 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 17.80 |
| 20-Day Moving Average | 16.63 |
| 10-Day Moving Average | 16.63 |
| Average True Range | 0.79 |
| RSI (14) | 44.44 |
| ADX | 13.99 |
| +DI | 15.94 |
| -DI | 18.67 |
| Chandelier Exit (Long, 3 ATRs) | 15.64 |
| Chandelier Exit (Short, 3 ATRs) | 17.92 |
| Upper Bollinger Bands | 17.34 |
| Lower Bollinger Band | 15.92 |
| Percent B (%b) | 0.51 |
| BandWidth | 8.54 |
| MACD Line | -0.28 |
| MACD Signal Line | -0.39 |
| MACD Histogram | 0.1125 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.63 | ||||
| Resistance 3 (R3) | 17.70 | 17.45 | 17.46 | ||
| Resistance 2 (R2) | 17.45 | 17.20 | 17.41 | 17.41 | |
| Resistance 1 (R1) | 17.05 | 17.05 | 16.93 | 16.98 | 17.35 |
| Pivot Point | 16.80 | 16.80 | 16.74 | 16.76 | 16.80 |
| Support 1 (S1) | 16.40 | 16.55 | 16.28 | 16.33 | 15.95 |
| Support 2 (S2) | 16.15 | 16.40 | 16.11 | 15.89 | |
| Support 3 (S3) | 15.75 | 16.15 | 15.84 | ||
| Support 4 (S4) | 15.68 |
